Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial

The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance. In China's Henan province, 26 hospitals participated in a randomized controlled trial. We included pat...

Full description

Saved in:
Bibliographic Details
Published inCritical care (London, England) Vol. 27; no. 1; pp. 232 - 15
Main Authors Liu, Shaohua, Wu, Ying, Qi, Shaoyan, Shao, Huanzhang, Feng, Min, Xing, Lihua, Liu, Hongmei, Gao, Yanqiu, Zhu, Zhiqiang, Zhang, Shuguang, Du, Yuming, Lu, Yibin, Yang, Jing, Chen, Pingyan, Sun, Tongwen
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 13.06.2023
BioMed Central
BMC
Subjects
Antibiotics
Bacteria
Carbapenem-resistant gram-negative bacteria
Care and treatment
Critical care
Diagnosis
Dosage and administration
Drug dosages
Drug resistance
Drug resistance in microorganisms
Drug utilization
Infections
Informed consent
Methods
Mortality
Optimization dose
Physicians
Plasma
Pneumonia
Polymyxin B
Prevention
Sepsis
Severe infection
Statistical analysis
Therapeutic drug monitoring
China
Optimization dose
Therapeutic drug monitoring
Severe infection
Carbapenem-resistant gram-negative bacteria
Polymyxin B
Online AccessGet full text

Cover

Abstract The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance. In China's Henan province, 26 hospitals participated in a randomized controlled trial. We included patients with sepsis caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) susceptible to polymyxin B. The patients were randomly divided into a high-dose (HD) group or a low-dose (LD) group and received 150 mg loading dose, 75 mg every 12 h and 100 mg loading dose, 50 mg every 12 h, respectively. TDM was employed to determine if the dose of polymyxin B needs adjustment based on the area under the concentration-time curve across 24 h at a steady state (ssAUC ) of 50-100 mg h/L. The primary outcome was the 14-day clinical response, and the secondary outcomes included 28- and 14-day mortality. This trial included 311 patients, with 152 assigned to the HD group and 159 assigned to the LD group. Intention-to-treat analysis showed that the 14-day clinical response was non-significant (p = 0.527): 95/152 (62.5%) in the HD group and 95/159 (59.7%) in the LD group. Kaplan-Meier's 180-day survival curve showed survival advantage in the HD group than in the LD group (p = 0.037). More patients achieved the target ssAUC in the HD than in the LD group (63.8% vs. 38.9%; p = 0.005) and in the septic shock subgroup compared to all subjects (HD group: 71.4% vs. 63.8%, p = 0.037; LD group: 58.3% vs. 38.9%, p = 0.0005). Also, the target AUC compliance was not correlated with clinical outcomes but with acute kidney injury (AKI) (p = 0.019). Adverse events did not differ between the HD and LD groups. A fixed polymyxin B loading dose of 150 mg and a maintenance dose of 75 mg every 12 h was safe for patients with sepsis caused by CR-GNB and improves long-term survival. The increased AUC was associated with increased incidence of AKI, and TDM results were valued to prevent AKI. Trial registration Trial registration ClinicalTrials.gov: ChiCTR2100043208, Registration date: January 26, 2021.
AbstractList The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance.BACKGROUNDThe appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance.In China's Henan province, 26 hospitals participated in a randomized controlled trial. We included patients with sepsis caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) susceptible to polymyxin B. The patients were randomly divided into a high-dose (HD) group or a low-dose (LD) group and received 150 mg loading dose, 75 mg every 12 h and 100 mg loading dose, 50 mg every 12 h, respectively. TDM was employed to determine if the dose of polymyxin B needs adjustment based on the area under the concentration-time curve across 24 h at a steady state (ssAUC0-24) of 50-100 mg h/L. The primary outcome was the 14-day clinical response, and the secondary outcomes included 28- and 14-day mortality.METHODSIn China's Henan province, 26 hospitals participated in a randomized controlled trial. We included patients with sepsis caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) susceptible to polymyxin B. The patients were randomly divided into a high-dose (HD) group or a low-dose (LD) group and received 150 mg loading dose, 75 mg every 12 h and 100 mg loading dose, 50 mg every 12 h, respectively. TDM was employed to determine if the dose of polymyxin B needs adjustment based on the area under the concentration-time curve across 24 h at a steady state (ssAUC0-24) of 50-100 mg h/L. The primary outcome was the 14-day clinical response, and the secondary outcomes included 28- and 14-day mortality.This trial included 311 patients, with 152 assigned to the HD group and 159 assigned to the LD group. Intention-to-treat analysis showed that the 14-day clinical response was non-significant (p = 0.527): 95/152 (62.5%) in the HD group and 95/159 (59.7%) in the LD group. Kaplan-Meier's 180-day survival curve showed survival advantage in the HD group than in the LD group (p = 0.037). More patients achieved the target ssAUC0-24 in the HD than in the LD group (63.8% vs. 38.9%; p = 0.005) and in the septic shock subgroup compared to all subjects (HD group: 71.4% vs. 63.8%, p = 0.037; LD group: 58.3% vs. 38.9%, p = 0.0005). Also, the target AUC compliance was not correlated with clinical outcomes but with acute kidney injury (AKI) (p = 0.019). Adverse events did not differ between the HD and LD groups.RESULTSThis trial included 311 patients, with 152 assigned to the HD group and 159 assigned to the LD group. Intention-to-treat analysis showed that the 14-day clinical response was non-significant (p = 0.527): 95/152 (62.5%) in the HD group and 95/159 (59.7%) in the LD group. Kaplan-Meier's 180-day survival curve showed survival advantage in the HD group than in the LD group (p = 0.037). More patients achieved the target ssAUC0-24 in the HD than in the LD group (63.8% vs. 38.9%; p = 0.005) and in the septic shock subgroup compared to all subjects (HD group: 71.4% vs. 63.8%, p = 0.037; LD group: 58.3% vs. 38.9%, p = 0.0005). Also, the target AUC compliance was not correlated with clinical outcomes but with acute kidney injury (AKI) (p = 0.019). Adverse events did not differ between the HD and LD groups.A fixed polymyxin B loading dose of 150 mg and a maintenance dose of 75 mg every 12 h was safe for patients with sepsis caused by CR-GNB and improves long-term survival. The increased AUC was associated with increased incidence of AKI, and TDM results were valued to prevent AKI. Trial registration Trial registration ClinicalTrials.gov: ChiCTR2100043208, Registration date: January 26, 2021.CONCLUSIONA fixed polymyxin B loading dose of 150 mg and a maintenance dose of 75 mg every 12 h was safe for patients with sepsis caused by CR-GNB and improves long-term survival. The increased AUC was associated with increased incidence of AKI, and TDM results were valued to prevent AKI. Trial registration Trial registration ClinicalTrials.gov: ChiCTR2100043208, Registration date: January 26, 2021.
The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance. In China's Henan province, 26 hospitals participated in a randomized controlled trial. We included patients with sepsis caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) susceptible to polymyxin B. The patients were randomly divided into a high-dose (HD) group or a low-dose (LD) group and received 150 mg loading dose, 75 mg every 12 h and 100 mg loading dose, 50 mg every 12 h, respectively. TDM was employed to determine if the dose of polymyxin B needs adjustment based on the area under the concentration-time curve across 24 h at a steady state (ssAUC.sub.0-24) of 50-100 mg h/L. The primary outcome was the 14-day clinical response, and the secondary outcomes included 28- and 14-day mortality. This trial included 311 patients, with 152 assigned to the HD group and 159 assigned to the LD group. Intention-to-treat analysis showed that the 14-day clinical response was non-significant (p = 0.527): 95/152 (62.5%) in the HD group and 95/159 (59.7%) in the LD group. Kaplan-Meier's 180-day survival curve showed survival advantage in the HD group than in the LD group (p = 0.037). More patients achieved the target ssAUC.sub.0-24 in the HD than in the LD group (63.8% vs. 38.9%; p = 0.005) and in the septic shock subgroup compared to all subjects (HD group: 71.4% vs. 63.8%, p = 0.037; LD group: 58.3% vs. 38.9%, p = 0.0005). Also, the target AUC compliance was not correlated with clinical outcomes but with acute kidney injury (AKI) (p = 0.019). Adverse events did not differ between the HD and LD groups. A fixed polymyxin B loading dose of 150 mg and a maintenance dose of 75 mg every 12 h was safe for patients with sepsis caused by CR-GNB and improves long-term survival. The increased AUC was associated with increased incidence of AKI, and TDM results were valued to prevent AKI.
Abstract Background The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance. Methods In China’s Henan province, 26 hospitals participated in a randomized controlled trial. We included patients with sepsis caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) susceptible to polymyxin B. The patients were randomly divided into a high-dose (HD) group or a low-dose (LD) group and received 150 mg loading dose, 75 mg every 12 h and 100 mg loading dose, 50 mg every 12 h, respectively. TDM was employed to determine if the dose of polymyxin B needs adjustment based on the area under the concentration–time curve across 24 h at a steady state (ssAUC0–24) of 50–100 mg h/L. The primary outcome was the 14-day clinical response, and the secondary outcomes included 28- and 14-day mortality. Results This trial included 311 patients, with 152 assigned to the HD group and 159 assigned to the LD group. Intention-to-treat analysis showed that the 14-day clinical response was non-significant (p = 0.527): 95/152 (62.5%) in the HD group and 95/159 (59.7%) in the LD group. Kaplan–Meier’s 180-day survival curve showed survival advantage in the HD group than in the LD group (p = 0.037). More patients achieved the target ssAUC0–24 in the HD than in the LD group (63.8% vs. 38.9%; p = 0.005) and in the septic shock subgroup compared to all subjects (HD group: 71.4% vs. 63.8%, p = 0.037; LD group: 58.3% vs. 38.9%, p = 0.0005). Also, the target AUC compliance was not correlated with clinical outcomes but with acute kidney injury (AKI) (p = 0.019). Adverse events did not differ between the HD and LD groups. Conclusion A fixed polymyxin B loading dose of 150 mg and a maintenance dose of 75 mg every 12 h was safe for patients with sepsis caused by CR-GNB and improves long-term survival. The increased AUC was associated with increased incidence of AKI, and TDM results were valued to prevent AKI. Trial registration Trial registration ClinicalTrials.gov: ChiCTR2100043208, Registration date: January 26, 2021.
The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance. In China's Henan province, 26 hospitals participated in a randomized controlled trial. We included patients with sepsis caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) susceptible to polymyxin B. The patients were randomly divided into a high-dose (HD) group or a low-dose (LD) group and received 150 mg loading dose, 75 mg every 12 h and 100 mg loading dose, 50 mg every 12 h, respectively. TDM was employed to determine if the dose of polymyxin B needs adjustment based on the area under the concentration-time curve across 24 h at a steady state (ssAUC ) of 50-100 mg h/L. The primary outcome was the 14-day clinical response, and the secondary outcomes included 28- and 14-day mortality. This trial included 311 patients, with 152 assigned to the HD group and 159 assigned to the LD group. Intention-to-treat analysis showed that the 14-day clinical response was non-significant (p = 0.527): 95/152 (62.5%) in the HD group and 95/159 (59.7%) in the LD group. Kaplan-Meier's 180-day survival curve showed survival advantage in the HD group than in the LD group (p = 0.037). More patients achieved the target ssAUC in the HD than in the LD group (63.8% vs. 38.9%; p = 0.005) and in the septic shock subgroup compared to all subjects (HD group: 71.4% vs. 63.8%, p = 0.037; LD group: 58.3% vs. 38.9%, p = 0.0005). Also, the target AUC compliance was not correlated with clinical outcomes but with acute kidney injury (AKI) (p = 0.019). Adverse events did not differ between the HD and LD groups. A fixed polymyxin B loading dose of 150 mg and a maintenance dose of 75 mg every 12 h was safe for patients with sepsis caused by CR-GNB and improves long-term survival. The increased AUC was associated with increased incidence of AKI, and TDM results were valued to prevent AKI. Trial registration Trial registration ClinicalTrials.gov: ChiCTR2100043208, Registration date: January 26, 2021.
Background The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance. Methods In China's Henan province, 26 hospitals participated in a randomized controlled trial. We included patients with sepsis caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) susceptible to polymyxin B. The patients were randomly divided into a high-dose (HD) group or a low-dose (LD) group and received 150 mg loading dose, 75 mg every 12 h and 100 mg loading dose, 50 mg every 12 h, respectively. TDM was employed to determine if the dose of polymyxin B needs adjustment based on the area under the concentration-time curve across 24 h at a steady state (ssAUC.sub.0-24) of 50-100 mg h/L. The primary outcome was the 14-day clinical response, and the secondary outcomes included 28- and 14-day mortality. Results This trial included 311 patients, with 152 assigned to the HD group and 159 assigned to the LD group. Intention-to-treat analysis showed that the 14-day clinical response was non-significant (p = 0.527): 95/152 (62.5%) in the HD group and 95/159 (59.7%) in the LD group. Kaplan-Meier's 180-day survival curve showed survival advantage in the HD group than in the LD group (p = 0.037). More patients achieved the target ssAUC.sub.0-24 in the HD than in the LD group (63.8% vs. 38.9%; p = 0.005) and in the septic shock subgroup compared to all subjects (HD group: 71.4% vs. 63.8%, p = 0.037; LD group: 58.3% vs. 38.9%, p = 0.0005). Also, the target AUC compliance was not correlated with clinical outcomes but with acute kidney injury (AKI) (p = 0.019). Adverse events did not differ between the HD and LD groups. Conclusion A fixed polymyxin B loading dose of 150 mg and a maintenance dose of 75 mg every 12 h was safe for patients with sepsis caused by CR-GNB and improves long-term survival. The increased AUC was associated with increased incidence of AKI, and TDM results were valued to prevent AKI. Trial registration Trial registration ClinicalTrials.gov: ChiCTR2100043208, Registration date: January 26, 2021. Keywords: Polymyxin B, Therapeutic drug monitoring, Carbapenem-resistant gram-negative bacteria, Severe infection, Optimization dose
BackgroundThe appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance.MethodsIn China’s Henan province, 26 hospitals participated in a randomized controlled trial. We included patients with sepsis caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) susceptible to polymyxin B. The patients were randomly divided into a high-dose (HD) group or a low-dose (LD) group and received 150 mg loading dose, 75 mg every 12 h and 100 mg loading dose, 50 mg every 12 h, respectively. TDM was employed to determine if the dose of polymyxin B needs adjustment based on the area under the concentration–time curve across 24 h at a steady state (ssAUC0–24) of 50–100 mg h/L. The primary outcome was the 14-day clinical response, and the secondary outcomes included 28- and 14-day mortality.ResultsThis trial included 311 patients, with 152 assigned to the HD group and 159 assigned to the LD group. Intention-to-treat analysis showed that the 14-day clinical response was non-significant (p = 0.527): 95/152 (62.5%) in the HD group and 95/159 (59.7%) in the LD group. Kaplan–Meier’s 180-day survival curve showed survival advantage in the HD group than in the LD group (p = 0.037). More patients achieved the target ssAUC0–24 in the HD than in the LD group (63.8% vs. 38.9%; p = 0.005) and in the septic shock subgroup compared to all subjects (HD group: 71.4% vs. 63.8%, p = 0.037; LD group: 58.3% vs. 38.9%, p = 0.0005). Also, the target AUC compliance was not correlated with clinical outcomes but with acute kidney injury (AKI) (p = 0.019). Adverse events did not differ between the HD and LD groups.ConclusionA fixed polymyxin B loading dose of 150 mg and a maintenance dose of 75 mg every 12 h was safe for patients with sepsis caused by CR-GNB and improves long-term survival. The increased AUC was associated with increased incidence of AKI, and TDM results were valued to prevent AKI.Trial registration Trial registration ClinicalTrials.gov: ChiCTR2100043208, Registration date: January 26, 2021.
ArticleNumber 232
Audience Academic
Author Lu, Yibin
Sun, Tongwen
Liu, Hongmei
Liu, Shaohua
Du, Yuming
Xing, Lihua
Gao, Yanqiu
Shao, Huanzhang
Zhu, Zhiqiang
Zhang, Shuguang
Chen, Pingyan
Yang, Jing
Wu, Ying
Qi, Shaoyan
Feng, Min
Author_xml – sequence: 1
  givenname: Shaohua
  surname: Liu
  fullname: Liu, Shaohua
– sequence: 2
  givenname: Ying
  surname: Wu
  fullname: Wu, Ying
– sequence: 3
  givenname: Shaoyan
  surname: Qi
  fullname: Qi, Shaoyan
– sequence: 4
  givenname: Huanzhang
  surname: Shao
  fullname: Shao, Huanzhang
– sequence: 5
  givenname: Min
  surname: Feng
  fullname: Feng, Min
– sequence: 6
  givenname: Lihua
  surname: Xing
  fullname: Xing, Lihua
– sequence: 7
  givenname: Hongmei
  surname: Liu
  fullname: Liu, Hongmei
– sequence: 8
  givenname: Yanqiu
  surname: Gao
  fullname: Gao, Yanqiu
– sequence: 9
  givenname: Zhiqiang
  surname: Zhu
  fullname: Zhu, Zhiqiang
– sequence: 10
  givenname: Shuguang
  surname: Zhang
  fullname: Zhang, Shuguang
– sequence: 11
  givenname: Yuming
  surname: Du
  fullname: Du, Yuming
– sequence: 12
  givenname: Yibin
  surname: Lu
  fullname: Lu, Yibin
– sequence: 13
  givenname: Jing
  surname: Yang
  fullname: Yang, Jing
– sequence: 14
  givenname: Pingyan
  surname: Chen
  fullname: Chen, Pingyan
– sequence: 15
  givenname: Tongwen
  surname: Sun
  fullname: Sun, Tongwen
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37312218$$D View this record in MEDLINE/PubMed
BookMark eNp9UstuFDEQHKEgkiz8AAdkiQuXCX6MPV4uKFnxiBSUiMfZ8tg9G0cz9mJ7EMsf8Nd4sxuUjRDywVZ3VXWXVcfVgQ8equo5wSeESPE6EYZ5U2PKatxwSmvxqDoiTDS15Iwf3HsfVscp3WBMWinYk-qQtYxQSuRR9fsqDOtx_dN5dIbyNUS9WqNOJ7Ao-F0BpuwMsnFaojF4l0N0fokKw-jYlbaHsY6QXMraZxTiUnuXxoQSrErxzUYFXX06qxefL7-gqL0No_tVBpjBeWf0gHJ0enhaPe71kODZ7p5V396_-7r4WF9cfjhfnF7Uhosm14S1FCRwqgkDbXphDGGm6VoGgvAWN8RS2jGMLYceWgLWCmhELxswtjUdm1XnW10b9I1aRTfquFZBO3VbKOsrHYvhAZRuZMs4psYwaGjbaYsbSQVoIueSlt6servVWk3dCNaAz1EPe6L7He-u1TL8UARTQTmnReHVTiGG7xOkrEaXDAyD9hCmpKikXOK5mJMCffkAehOm6MtfbVAtwWy70g611MWB830og81GVJ22nM6ZkEwW1Mk_UOVYGJ0pMetdqe8RXtx3-tfiXZIKQG4BJoaUIvTKuKyzCxvjbiiO1Sa0ahtaVUKrbkOrRKHSB9Q79f-Q_gAFa-8O
CitedBy_id crossref_primary_10_1007_s15010_024_02365_z
crossref_primary_10_3389_fmicb_2023_1226981
crossref_primary_10_62347_WBZU4331
crossref_primary_10_1128_aac_01859_24
crossref_primary_10_3389_fphar_2024_1406043
crossref_primary_10_1016_j_ijantimicag_2024_107099
crossref_primary_10_1016_j_ijantimicag_2024_107418
crossref_primary_10_3390_antibiotics13030261
crossref_primary_10_1093_ndt_gfae069_827
crossref_primary_10_3389_fmed_2024_1400757
crossref_primary_10_12677_acm_2024_1451528
crossref_primary_10_3389_fphar_2024_1347130
crossref_primary_10_1016_j_cej_2025_161122
Cites_doi 10.1007/s00134-021-06506-y
10.1016/j.diagmicrobio.2018.01.005
10.1097/ftd.0000000000000754
10.1056/EVIDoa2200131
10.2147/IDR.S357746
10.3389/fphar.2020.00829
10.1128/AAC.01337-16
10.1128/AAC.00844-15
10.1016/j.ijantimicag.2022.106599
10.1159/000339789
10.1002/phar.2209
10.1186/s13054-022-04195-7
10.1016/j.cmi.2021.11.025
10.1086/592577
10.1093/jac/dku561
10.1093/jac/dkq285
10.1128/CMR.00006-08
10.1093/jac/dkq226
10.1128/AAC.00208-17
10.1093/cid/cit334
10.1111/jcpt.13711
10.2147/DDDT.S313714
10.1007/s00134-017-4683-6
10.3390/antibiotics9080451
10.1186/s12967-021-03111-x
10.1016/s1473-3099(17)30753-3
10.1093/jac/dkm357
10.1128/AAC.00483-18
10.1056/NEJMp1215093
10.1128/aac.01493-17
10.1111/bcp.14576
10.1016/s1473-3099(18)30099-9
10.3389/fmed.2021.620885
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13054-023-04522-6
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials Local Electronic Collection Information
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


PubMed

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1364-8535
1466-609X
1366-609X
EndPage 15
ExternalDocumentID oai_doaj_org_article_a4873502cc3e427bad04826ea1898287
PMC10262552
A752936838
37312218
10_1186_s13054_023_04522_6
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: the United Fund of National Natural Science Foundation of China
  grantid: U2004110
– fundername: Medical Science and Technology Tackling Plan Provincial and Ministerial Major Projects of Henan Province
  grantid: SBGJ202101015)
– fundername: The central government guides local science and technology development funds
  grantid: Z20221343037
– fundername: National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
  grantid: 82172129
– fundername: ;
  grantid: 82172129
– fundername: ;
  grantid: SBGJ202101015)
– fundername: ;
  grantid: U2004110
– fundername: ;
  grantid: Z20221343037
GroupedDBID ---
0R~
29F
2WC
4.4
53G
5GY
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABUWG
ACGFS
ACJQM
ADBBV
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EBD
EBLON
EBS
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
OK1
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SJN
SMD
SOJ
SV3
TR2
U2A
UKHRP
WOQ
YOC
NPM
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c564t-1372e8e52a13eacf6cc13c4b73e6157041d22b300d5efe71edd6e46f84ecd7cb3
IEDL.DBID 7X7
ISSN 1364-8535
1466-609X
IngestDate Wed Aug 27 01:20:29 EDT 2025
Thu Aug 21 18:37:21 EDT 2025
Thu Jul 10 23:51:45 EDT 2025
Fri Jul 25 04:14:43 EDT 2025
Tue Jun 17 21:48:01 EDT 2025
Tue Jun 10 20:41:27 EDT 2025
Thu Apr 03 07:04:39 EDT 2025
Tue Jul 01 03:55:07 EDT 2025
Thu Apr 24 22:51:41 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Optimization dose
Therapeutic drug monitoring
Severe infection
Carbapenem-resistant gram-negative bacteria
Polymyxin B
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-1372e8e52a13eacf6cc13c4b73e6157041d22b300d5efe71edd6e46f84ecd7cb3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Undefined-1
content type line 23
OpenAccessLink https://www.proquest.com/docview/2827103287?pq-origsite=%requestingapplication%
PMID 37312218
PQID 2827103287
PQPubID 44362
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_a4873502cc3e427bad04826ea1898287
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10262552
proquest_miscellaneous_2825809691
proquest_journals_2827103287
gale_infotracmisc_A752936838
gale_infotracacademiconefile_A752936838
pubmed_primary_37312218
crossref_citationtrail_10_1186_s13054_023_04522_6
crossref_primary_10_1186_s13054_023_04522_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-06-13
PublicationDateYYYYMMDD 2023-06-13
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-13
  day: 13
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Critical care (London, England)
PublicationTitleAlternate Crit Care
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References V Thamlikitkul (4522_CR18) 2017
AP Zavascki (4522_CR4) 2007; 60
BT Tsuji (4522_CR6) 2019; 39
P Wang (4522_CR20) 2022; 60
SS Richter (4522_CR13) 2018; 91
E Tacconelli (4522_CR2) 2018; 18
BC Nelson (4522_CR30) 2015; 59
P Wang (4522_CR16) 2020; 11
A Khwaja (4522_CR21) 2012; 120
P Wang (4522_CR15) 2020; 42
S Kaye Keith (4522_CR32) 2022; 2
J Yang (4522_CR24) 2022; 26
B Spellberg (4522_CR1) 2013; 368
NJ Onufrak (4522_CR7) 2017
LS Elias (4522_CR28) 2010; 65
AM Sandri (4522_CR12) 2013; 57
M Paul (4522_CR3) 2022; 28
Y Cai (4522_CR29) 2020
CJ Kubin (4522_CR8) 2018
X Wu (4522_CR31) 2021; 15
AP Zavascki (4522_CR17) 2008; 47
MH Rigatto (4522_CR27) 2015; 70
X Zhang (4522_CR11) 2021; 19
RV Dudhani (4522_CR26) 2010; 65
D Landman (4522_CR5) 2008; 21
M Paul (4522_CR19) 2018; 18
A Rhodes (4522_CR14) 2017; 43
EA Lakota (4522_CR9) 2018
L Evans (4522_CR25) 2021; 47
XB Yu (4522_CR22) 2021; 87
J Qu (4522_CR10) 2022; 15
Q Ye (4522_CR23) 2022; 47
Q Lu (4522_CR33) 2021; 8
References_xml – volume: 47
  start-page: 1181
  issue: 11
  year: 2021
  ident: 4522_CR25
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-021-06506-y
– volume: 91
  start-page: 89
  issue: 1
  year: 2018
  ident: 4522_CR13
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2018.01.005
– volume: 42
  start-page: 716
  issue: 5
  year: 2020
  ident: 4522_CR15
  publication-title: Ther Drug Monit
  doi: 10.1097/ftd.0000000000000754
– volume: 2
  start-page: 2200131
  issue: 1
  year: 2022
  ident: 4522_CR32
  publication-title: NEJM Evidence
  doi: 10.1056/EVIDoa2200131
– volume: 15
  start-page: 1205
  year: 2022
  ident: 4522_CR10
  publication-title: Infect Drug Resist
  doi: 10.2147/IDR.S357746
– volume: 11
  start-page: 829
  year: 2020
  ident: 4522_CR16
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2020.00829
– year: 2017
  ident: 4522_CR18
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01337-16
– volume: 59
  start-page: 7000
  issue: 11
  year: 2015
  ident: 4522_CR30
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00844-15
– volume: 60
  start-page: 106599
  issue: 1
  year: 2022
  ident: 4522_CR20
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2022.106599
– volume: 120
  start-page: c179
  issue: 4
  year: 2012
  ident: 4522_CR21
  publication-title: Nephron Clin Pract
  doi: 10.1159/000339789
– volume: 39
  start-page: 10
  issue: 1
  year: 2019
  ident: 4522_CR6
  publication-title: Pharmacotherapy
  doi: 10.1002/phar.2209
– volume: 26
  start-page: 320
  issue: 1
  year: 2022
  ident: 4522_CR24
  publication-title: Crit Care
  doi: 10.1186/s13054-022-04195-7
– volume: 28
  start-page: 521
  issue: 4
  year: 2022
  ident: 4522_CR3
  publication-title: Clin Microbiol Infect
  doi: 10.1016/j.cmi.2021.11.025
– volume: 47
  start-page: 1298
  issue: 10
  year: 2008
  ident: 4522_CR17
  publication-title: Clin Infect Dis
  doi: 10.1086/592577
– volume: 70
  start-page: 1552
  issue: 5
  year: 2015
  ident: 4522_CR27
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dku561
– volume: 65
  start-page: 2231
  issue: 10
  year: 2010
  ident: 4522_CR28
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkq285
– volume: 21
  start-page: 449
  issue: 3
  year: 2008
  ident: 4522_CR5
  publication-title: Clin Microbiol Rev
  doi: 10.1128/CMR.00006-08
– volume: 65
  start-page: 1984
  issue: 9
  year: 2010
  ident: 4522_CR26
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkq226
– year: 2017
  ident: 4522_CR7
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00208-17
– volume: 57
  start-page: 524
  issue: 4
  year: 2013
  ident: 4522_CR12
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cit334
– volume: 47
  start-page: 1608
  issue: 10
  year: 2022
  ident: 4522_CR23
  publication-title: J Clin Pharm Ther
  doi: 10.1111/jcpt.13711
– volume: 15
  start-page: 2593
  year: 2021
  ident: 4522_CR31
  publication-title: Drug Des Devel Ther
  doi: 10.2147/DDDT.S313714
– volume: 43
  start-page: 304
  issue: 3
  year: 2017
  ident: 4522_CR14
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-017-4683-6
– year: 2020
  ident: 4522_CR29
  publication-title: Antibiotics
  doi: 10.3390/antibiotics9080451
– volume: 19
  start-page: 431
  issue: 1
  year: 2021
  ident: 4522_CR11
  publication-title: J Transl Med
  doi: 10.1186/s12967-021-03111-x
– volume: 18
  start-page: 318
  issue: 3
  year: 2018
  ident: 4522_CR2
  publication-title: Lancet Infect Dis
  doi: 10.1016/s1473-3099(17)30753-3
– volume: 60
  start-page: 1206
  issue: 6
  year: 2007
  ident: 4522_CR4
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkm357
– year: 2018
  ident: 4522_CR9
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00483-18
– volume: 368
  start-page: 299
  issue: 4
  year: 2013
  ident: 4522_CR1
  publication-title: N Engl J Med
  doi: 10.1056/NEJMp1215093
– year: 2018
  ident: 4522_CR8
  publication-title: Antimicrob Agents Chemother.
  doi: 10.1128/aac.01493-17
– volume: 87
  start-page: 1869
  issue: 4
  year: 2021
  ident: 4522_CR22
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.14576
– volume: 18
  start-page: 391
  issue: 4
  year: 2018
  ident: 4522_CR19
  publication-title: Lancet Infect Dis
  doi: 10.1016/s1473-3099(18)30099-9
– volume: 8
  start-page: 620885
  year: 2021
  ident: 4522_CR33
  publication-title: Front Med.
  doi: 10.3389/fmed.2021.620885
SSID ssj0017863
Score 2.4691424
Snippet The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under...
Background The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under...
BackgroundThe appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under...
Abstract Background The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 232
SubjectTerms Antibiotics
Bacteria
Carbapenem-resistant gram-negative bacteria
Care and treatment
Critical care
Diagnosis
Dosage and administration
Drug dosages
Drug resistance
Drug resistance in microorganisms
Drug utilization
Infections
Informed consent
Methods
Mortality
Optimization dose
Physicians
Plasma
Pneumonia
Polymyxin B
Prevention
Sepsis
Severe infection
Statistical analysis
Therapeutic drug monitoring
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yB_EifltdJYLgQco2SZuk3nYWl0UYXdSFvYU0SXVg2w7bGXD2P9j_2vfSzjBF0IvXfDbJ-2zyfo-Qt7XPKmelT0uv8zT3dZZWXJTgpTBrpeVVGbE755_l2UX-6bK43Ev1hW_CBnjgYeOOLFjUosi4cyLkXFXWA81xGSzTJYK1o_QFnbd1psb7A6Wl2IbIaHnUg6Qu8hT0UxohxFM5UUMRrf9PmbynlKYPJvc00OkDcn80Henx8MkPyZ3QPiJ35-Pl-GNye95dbZrNr0VLZ3SIq9pQ1FKedi3dC7Si_nr9gzaRm_G3HoUeDu8dliD4mhQccDQq2xUdUj71TU_7sITCDzgKPZ_P0pOvX75RUHO-axY3MME2wJLGLCBPyMXpx-8nZ-mYaSF1hcwxH73iQYeCWyZAEtfSOSZcXikRwOJRWc4855XIMl-EOigWvJchl7XOg_PKVeIpOWi7NjwntCzRQ6t4LUsLAzCNADOIC8iF1Z65hLDtxhs3wpBjNowrE90RLc1wWAYOy8TDMjIh73d9lgMIx19bz_A8dy0RQDsWwKaZkazMv8gqIe-QGgyyOXyes2O0AiwSAbPMsSrAUJJa6IQcTloCe7pp9ZaezCgeegN-ropIhjDPm1019sQnb23o1rFNocHBLFlCng3kt1uSUIJxMM4SoieEOVnztKZd_Izg4WBQgstb8Bf_Y5dekns8MhViWR6Sg9X1OrwCI21VvY78-Bv3ETfc
  priority: 102
  providerName: Directory of Open Access Journals
Title Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial
URI https://www.ncbi.nlm.nih.gov/pubmed/37312218
https://www.proquest.com/docview/2827103287
https://www.proquest.com/docview/2825809691
https://pubmed.ncbi.nlm.nih.gov/PMC10262552
https://doaj.org/article/a4873502cc3e427bad04826ea1898287
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFLdgkxAXxDeBURkJiQOyVtuJ7XBB67RpQuqoCpMqLlFiO1BpTcrSSpT_gP-a95y0NELaJYfYTuK8b9vv9wh5W7phYXPlWOpMzGJXDlkhZApRCs9zlYsiDdid40t1cRV_miWzbsGt6Y5VbnViUNSutrhGfgyhgQ7gb_rj8ifDqlG4u9qV0LhLDhG6DI906dku4OLahEpqXKqYgVlKtkkzRh03oLuTmIHFYgFUnKmeYQr4_f9r6T0z1T9CuWeTzh-SB50zSU9a6j8id3z1mNwbd9vlT8ifSX29WWx-zSs6om2m1Yai3XK0ruhe6hV1N-vvdBHkGxf6KIywuBOxBFW4YBCSo5tZrWhbBKpZNLTxS7j5AZ9CJ-MRO51-_kLB8Ll6Mf8NL9imXNJQF-QpuTo_-3p6wbraC8wmKsYK9Vp44xORcwm6uVTWcmnjQksPPpAextwJUcjh0CW-9Jp755SPVWlib522hXxGDqq68i8ITVOM2QpRqjSHB3CDkDOIFChkbhy3EeHbH5_ZDpgc62NcZyFAMSpriZUBsbJArExF5P1uzLKF5bi19wjpueuJkNrhBvy0rJPQLIfQTSZDYa30sdBF7kC5CeVzblKsChCRd8gNGQo-fJ7Nu_wFmCRCaGUnOgHXSRlpInLU6wkCa_vNW37KOoXRZP_YOyJvds04Eg_BVb5ehz6JgZAz5RF53rLfbkpSSy7AXYuI6TFmb879lmr-I8CJg4sJQXAiXt7-Xa_IfRHEBXErj8jB6mbtX4NDtioGQeoG5HB0djmZDsKyBlyno29_AYzXNdo
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJwEviP8EBhgJxAOyltiJ4yAhtI5NHVvLNDZpbyaxHai0JqVpBeUb8GX4jJydpDRC2tteYzuJc-ff3cW-3yH0Mtd-plKuSaJFSEKd-ySjLIEoJUhTntIscdydwxEfnIUfz6PzDfSnzYWxxypbTHRArUtl_5FvQ2gQO_K3-P30O7FVo-zualtCo1aLQ7P8ASFb9e7gA8j3FaX7e6e7A9JUFSAq4qGtvR5TI0xE04AB6uRcqYCpMIuZAese-2GgKc2Y7-vI5CYOjNbchDwXoVE6VhmD-15DmyGDUKaHNvt7o-OT1b5FLFzttoDxkIAhjNo0HcG3K7AWUUjARhJHY054xxS6igH_24U1w9g9tLlmBfdvo1uN-4p3an27gzZMcRddHzYb9PfQ7-PyYjlZ_hwXuI_r3K4ltpZS47LAa8leWM8WX_HEIYr9tYhhhLJ7H1MA3wmZmco6tsUc12WnqkmFKzOFi2_tXfDxsE92Tz59xmBqdTkZ_4IHtEme2FUiuY_OrkQuD1CvKAvzCOEksVFiRnOepHCDQFiSG8tNSFkqdKA8FLQfXqqGCt1W5LiQLiQSXNbCkiAs6YQluYferMZMayKQS3v3rTxXPS2Jt7sAH002mCBTCBZZ5FOlmAlpnKUa4JRykwYisXUIPPTaaoO0UAOvp9ImYwImaUm75E4cgbPGBRMe2ur0BIhQ3eZWn2QDUZX8t6A89GLVbEfaY3eFKReuTyQgyE0CDz2s1W81JRazgIKD6CHRUczOnLstxfibIzAHpxbC7og-vvy9nqMbg9PhkTw6GB0-QTepWzqWNXML9eazhXkK7uA8e9asQYy-XPWy_wuEQHGl
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polymyxin+B+therapy+based+on+therapeutic+drug+monitoring+in+carbapenem-resistant+organisms+sepsis%3A+the+PMB-CROS+randomized+clinical+trial&rft.jtitle=Critical+care+%28London%2C+England%29&rft.au=Liu%2C+Shaohua&rft.au=Wu%2C+Ying&rft.au=Qi%2C+Shaoyan&rft.au=Shao%2C+Huanzhang&rft.date=2023-06-13&rft.pub=BioMed+Central&rft.issn=1364-8535&rft.eissn=1366-609X&rft.volume=27&rft.spage=1&rft_id=info:doi/10.1186%2Fs13054-023-04522-6
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1364-8535&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1364-8535&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1364-8535&client=summon